Athough new molecules have advanced the treatment of Hodgkin lymphoma considerably in recent years, research is still ongoing to achieve the best possible outcomes for patients. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the key treatments for Hodgkin lymphoma currently, including pembrolizumab, nivolumab and brentuximab.
Latest research in Hodgkin lymphoma
